INVST’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

INVST’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,800	Closed	-$76K	–	230
2021 Q3	$76K	Hold	11,800	–	–	0.01%	191
2021 Q2	$72K	Buy	+11,800	New	+$95.2K	0.01%	192

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

INVST's PRVB Position: Q4 2021 in Review

INVST sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2021, closing a stake of 11,800 shares — an estimated $76K sold.

INVST first reported a position in PRVB in Q2 2021 and held it in 2 quarters. The position peaked at $76K in Q3 2021. 112 funds tracked by Wall St. Rank hold PRVB as of Q4 2021.

INVST reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
INVST sold 11,800 Provention Bio, Inc. Common Stock shares in Q4 2021, an estimated $76K.
INVST first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
INVST's Provention Bio, Inc. Common Stock position peaked at $76K in Q3 2021.
112 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2021.

Based on INVST's 13F filing for Q4 2021, filed 25 Feb 2022.